GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
Trial Timeline
May 1, 2016 → Dec 31, 2022
NCT ID
NCT02759588About GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab is a phase 1/2 stage product being developed by Genelux for Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02759588. Target conditions include Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer.
What happened to similar drugs?
11 of 20 similar drugs in Ovarian Cancer were approved
Approved (11) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
9
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02759588 | Phase 1/2 | Completed |
Competing Products
20 competing products in Ovarian Cancer